Position in CLDI
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2
-$10,028 QoQ
Shares Held
633
+178.9% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLDI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HRT FINANCIAL LP holds $857,555,842 across 185 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,089,376 | $81,136,724 | |
| 2 | INSM |
INSMED Inc
|
689,981 | $73,565,774 | |
| 3 | EXEL |
Exelixis, Inc.
|
929,242 | $50,560,057 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
84,634 | $45,444,226 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
178,491 | $43,689,242 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
498,655 | $40,645,369 | |
| 7 | ABVX |
Abivax S.A.
|
270,612 | $36,061,755 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
622,603 | $34,205,808 |
All Filings in CLDI
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2 | 10,133 | Shares | Defined | 2026-05-14 | |
| 2025-06-30 | $10,030 | 43,609 | Shares | Defined | 2025-08-14 | |
| 2024-12-31 | $18,113 | 15,751 | Shares | Defined | 2025-02-14 | |
| 2024-06-30 | $20,277 | 101,390 | Shares | Defined | 2024-08-12 | |
| 2024-03-31 | $7 | 14,071 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $25,004 | 16,559 | Shares | Defined | 2024-02-09 | |
| 2023-09-30 | $34,284 | 10,311 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $113,470 | 10,817 | Shares | Defined | 2023-08-11 | |
| 2023-03-31 | $111,090 | 10,817 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $110,008 | 10,817 | Shares | Defined | 2023-02-10 | |
| 2022-09-30 | $107,542 | 10,918 | Shares | Defined | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||